Novo traded 4% lower on the news Friday. Diabetes drug Ozempic and weight-loss drug Wegovy top the list, along with a number of others like Merck's (MRK) diabetes drug Janumet. "The Biden-Harris ...

That is when a new study of the drug is also planned — details were shared in Novo's earnings presentation, released today, and Redefine 4 study results have been promised for H225. Novo stock ...

That haul helped Novo’s total sales for 2024 grow 26% at constant currencies to 290.4 billion kroner (nearly $41 billion), contributing to operating profits of 128.3 billion kroner ($18 billion ...

LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk (NVO) forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, with analysts and investors ...

The most recent Pod 4 Ultra is currently $150 off all sizes at Eight Sleep. Aimed at hot sleepers and those who want to understand what happens within their sleeping body, the Eight Sleep Pod 4 ...

Novo Nordisk closed up 4.5% Wednesday. Shares of obesity drug rival Eli Lilly, meanwhile, rose 1.4%. Speaking to CNBC Wednesday, CEO and President Lars Fruergaard Jørgensen said that the company ...

Despite the company’s enthusiasm, questions remain about how Novo's latest numbers can move the needle in a competitive market. The company's stock price decline of 4% on Friday seems to ...

Novo Nordisk Q4 sales rose 30% to around $12 billion. GLP-1 diabetes sales grew 12% to DKK42.2 billion, while obesity drug sales surged 91% to DKK 21.4 billion. Get access to your new suite of ...

In this video, I will go over Novo Nordisk's (NVO-3.62%) and Eli Lilly's recent earnings report. Watch the short video to learn more, consider subscribing, and click the special offer link below.

Novo Nordisk (NVO) announced Friday that its popular ... the Danish drugmaker said that while patients on regular Wegovy at 2.4 mg achieved 17.5% weight loss over the period, those on placebo ...